Bicara Therapeutics
BCAX
140 hedge funds and large institutions have $961M invested in Bicara Therapeutics in 2025 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 45 increasing their positions, 35 reducing their positions, and 17 closing their positions.
159% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 17
29% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 35
23% more funds holding
Funds holding: 114 → 140 (+26)
21% more capital invested
Capital invested by funds: $792M → $961M (+$168M)
12.21% more ownership
Funds ownership: 92% → 104.21% (+12%)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
100% less call options, than puts
Call options by funds: $7K | Put options by funds: $3.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$47.3M |
| 2 |
Janus Henderson Group
London,
|
+$45.2M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$27.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$18.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$26M |
| 2 |
Blackstone Inc
New York
|
-$19.3M |
| 3 |
Millennium Management
New York
|
-$9.91M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$7.96M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$4.21M |
BCAX Hedge Fund Activity: Q4 2025 in Review
140 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Bicara Therapeutics (BCAX) for Q4 2025, worth a combined $961M — up 21% from $792M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new BCAX positions and 17 closed out — a net gain of 27 holders — while 45 added to existing stakes and 35 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $47.3M. The largest seller was Vestal Point Capital, cutting an estimated $26M.
- 140 institutional investors held Bicara Therapeutics (BCAX) as of Q4 2025, up from 114 in Q3 2025.
- Funds reported $961M of Bicara Therapeutics stock for Q4 2025, up 21% quarter-over-quarter.
- 44 funds opened new Bicara Therapeutics positions in Q4 2025 and 17 closed out, a net change of +27 holders.
- The largest Bicara Therapeutics buyer in Q4 2025 was T. Rowe Price Investment Management, an estimated $47.3M added.
- The largest Bicara Therapeutics seller in Q4 2025 was Vestal Point Capital, an estimated $26M sold.
Based on aggregated 13F filings for Q4 2025.